Search

Pages

1. • Journal article

   • 

   Immunity to live: an immunopathoscore using the consensus Immunoscore to best define the risk of recurrence and death in stage IV metastatic patients.

   Baldin, Paméla[UCL] Van den Eynde, Marc[UCL] Mlecnik, Bernhard Galon, Jérôme (2020) Oncoimmunology — Vol. 9, no.1, p. 1826133 [1-3] (2020)
2. • Speech

   • 

   Unusual liver masses in two women

   Dano, Hélène[UCL] Théate, Ivan[UCL] Van den Eynde, Marc[UCL] Lambert, Michel[UCL] Rahier, Jacques[UCL] Annet, Laurence[UCL] Sempoux, Christine[UCL] (2012) Belgian Week of Gastroenterology - XXIVth Edition — (Belgium) Ostend
3. • Speech

   • 

   Radioembolization using Yttrium 90 microspheres for unresectable liver metastases: a single centre experience

   Gokburun, Yeter[UCL] Zech, Francis[UCL] Lhommel, Renaud[UCL] Borbath, Ivan[UCL] Demorcy, Marianne[UCL] Goffette, Pierre[UCL] Van den Eynde, Marc[UCL] (2017) Belgian Week of Gastroenterology - XXIXth edition — (Belgium) Antwerp
4. • Journal article

   • 

   Les traitements anti-EGFR en cancérologie digestive

   Van den Eynde, Marc[UCL] Humblet, Yves[UCL] Machiels, Jean-Pascal[UCL] (2011) Onco Hemato — Vol. 5, p. 270-275 (2011)
5. • Speech

   • 

   599P R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)

   Carrasco, Javier Beniuga, Gabriela[UCL] Mourin, Anne[UCL] Baldin, Paméla[UCL] Sinapi, Isabelle Schroeder, David De Cuyper, Astrid[UCL] Sclafani, Francesco Hendlisz, Alain van Laethem, Jean-Luc Boulanger, Anne-Sophie Van Ooteghem, Geneviève[UCL] Dermine, Alexandre Delmarcelle, Sophie Huyghe, Nicolas[UCL] Bar, Isabelle Van den Eynde, Marc[UCL] (2023) ESMO Congress 2023 — (Spain) Madrid
6. • Journal article

   • 

   Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study.

   Ajani, Jaffer El Hajbi, Farid Cunningham, David Alsina, Maria Thuss-Patience, Peter Scagliotti, Giorgio V Van den Eynde, Marc[UCL] Kim, Sung-Bae Kato, Ken Shen, Lin Li, Liyun Ding, Ningning Shi, Jingwen Barnes, Gisoo Van Cutsem, Eric (2024) ESMO open — Vol. 9, no.1, p. 102202 [1-9] (2024)
7. • Speech

   • 

   PD-1 MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress)

   Siena, S. Elez, E. Peeters, M. André, T. Van den Eynde, Marc[UCL] Ng, K. Cercek, A. Fountzilas, C. Sanchez, F. Hubbard, J. Wu, C. Tabernero, J. Kardosh, A. Saeed, A. Strickler, J. Bekaii-Saab, T. Stecher, M. Palanca-Wessels, M. Van Cutsem, E. (2021) ESMO World Congress on Gastrointestinal Cancer 2021 —
8. • Journal article

   • 

   Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

   Eng, Cathy Kim, Tae Won Bendell, Johanna Argilés, Guillem Tebbutt, Niall C Di Bartolomeo, Maria Falcone, Alfredo Fakih, Marwan Kozloff, Mark Segal, Neil H Sobrero, Alberto Yan, Yibing Chang, Ilsung Uyei, Anne Roberts, Louise Ciardiello, Fortunato Ahn, JB Asselah, J Badarinath, S Baijal, S Begbie, S Berry, S Canon, JL Carbone, RG Cervantes, A Cha, YJ Chang, K Chaudhry, A Chmielowska, E Cho, SH Chu, D Couture, F Cultrera, J Cunningham, D Van Cutsem, E Cuyle, PJ Davies, J Dowden, S Dvorkin, M Ganju, V Garcia, RV Kerr, R Kim, TY King, K Kortmansky, J Kozloff, M Lam, KO Lee, J Lee, AS Lesperance, B Luppi, G Ma, B Maiello, E Mandanas, R Marshall, J Marx, G Mullamitha, S Nechaeva, M Park, JO Pavlakis, N Ponce, CG Potemski, P Raouf, S Reeves, J Segal, N Siena, S Smolin, A Streb, JO Strickland, A Szutowicz-Zielinska, E Tabernero, JM Tan, B Valera, JS Van den Eynde, Marc[UCL] Vergauwe, P Vickers, M Womack, M Wroblewska, M Young, R (2019) The Lancet Oncology — Vol. 20, no.6, p. 849-861 (2019)
9. • Speech

   • 

   Clinico-pathological characterization of patients with colorectal cancer and restricted immunohistochemistry overexpression of p53

   Van den Bossche, V. Van den Eynde, Marc[UCL] van Maanen, Aline[UCL] Kartheuser, Alex[UCL] Léonard, Daniel[UCL] Remue, Christophe[UCL] Mourin, Anne[UCL] (2016) Belgian Week of Gastroenterology - XXVIIIth edition — (Belgium) Bruxelles
10. • Journal article

    • 

    Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer.

    Bourhis, Jean Stein, Alexander Paul de Boer, Jan Van den Eynde, Marc[UCL] Gold, Kathryn A Stintzing, Sebastian Becker, Jürgen C Moran, Michael Schroeder, Andreas Pennock, Gregory Salmio, Satu Esser, Regina Ciardiello, Fortunato (2021) Cancer treatment reviews — Vol. 97, p. 102172 [1-9] (2021)
11. • Speech

    • 

    Comparison of Pathological Responses (PR) Observed on Colorectal Cancer Metastases (CRCM) Resected After Different Preoperative Treatments

    Van den Eynde, Marc[UCL] Gizzi, M. Pairet, G. Lefesvre, P. Lannoy, V. Gigot, J. Navez, Benoît[UCL] Canon, J. Sempoux, C. Carrasco, J. (2012) ESMO Congress 2012 —
12. • Journal article

    • 

    Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial

    Aparicio, Thomas Bouché, Olivier Etienne, Pierre-Luc Barbier, Emilie Mineur, Laurent Desgrippes, Romain Guérin-Meyer, Véronique Hocine, Fayçal Martin, Jean Le Brun-Ly, Valérie Cretin, Jacques Desramé, Jérôme Rinaldi, Yves Cany, Laurent Falandry, Claire Lefevre, Leila Bengrine Marous, Miguelle Terrebonne, Eric Mosser, Laurent Turpin, Justine Turpin, Anthony Bauguion, Lucille Reichling, Cynthia Van den Eynde, Marc[UCL] Carola, Elisabeth Hiret, Sandrine (2023) Digestive and liver disease — Vol. 55, no. 4, p. 541-548 (2023)
13. • Speech

    • 

    O16 Immunoscore® Colon analytical performance

    Van den Eynde, Marc[UCL] (2016) 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) — National Harbor, MD, USA.
14. • Speech

    • 

    Preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer: Preliminary analysis of the PePiTA study.

    Hendlisz, Alain Caparica, Rafael Deleporte, Amélie Van Laethem, Jean-Luc Vergauwe, Philippe Van den Eynde, Marc[UCL] Deboever, Guido Janssens, Jozef Demolin, Gauthier Holbrechts, Stephane Clausse, Marylene De Grez, Thierry Vermeij, Joanna D'Hondt, Lionel A. Geboes, Karen Paula Besse-Hammer, Tatiana Buggenhout, Alexis Paesmans, Marianne Piccart, Martine Flamen, Patrick (2019) 2019 ASCO Annual Meeting I - GASTROINTESTINAL (COLORECTAL) CANCER —
15. • Speech

    • 

    Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)—A proof of concept, open-label, nonrandomized phase IIa study.

    Van den Eynde, Marc[UCL] Huyghe, Nicolas De Cuyper, Astrid[UCL] Sinapi, Isabelle Ferrier, Marie Gilet, Mélanie Van Maanen, Aline[UCL] Castella, Marie-Laure[UCL] Galon, Jerome Carrasco, Javier (2021) 2021 Gastrointestinal Cancers Symposium —
16. • Speech

    • 

    REGINA: A phase II trial of neoadjuvant regorafenib (Rego) in combination with nivolumab (Nivo) and short-course radiotherapy (SCRT) in intermediate-risk, stage II-III rectal cancer (RC).

    Bregni, Giacomo Senti, Chiara Acedo Reina, Elena Gkolfakis, Paraskevas Moretti, Luigi Veron, Ana Demetter, Pieter Liberale, Gabriel Carrasco, Javier Geboes, Karen Paula Gokburun, Yeter Peeters, Marc Van den Eynde, Marc[UCL] Van Laethem, Jean-Luc Vergauwe, Philippe Buyse, Marc E. Deleporte, Amélie Hendlisz, Alain Sclafani, Francesco (2022) 2022 ASCO Gastrointestinal Cancers Symposium —
17. • Speech

    • 

    Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).

    Raghav, Kanwal Pratap Singh Yoshino, Takayuki Guimbaud, Rosine Chau, Ian Van den Eynde, Marc[UCL] Maurel, Joan Tie, Jeanne Kim, Tae Won Yeh, Kun-Huei Barrios, Daniel Kobayashi, Kojiro Bako, Emarjola Aregay, Mehreteab Meinhardt, Gerold Siena, Salvatore (2021) 2021 ASCO Annual Meeting I —
18. • Journal article

    • 

    Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

    Huyghe, Nicolas[UCL] Benidovskaya, Elena[UCL] Beyaert, Simon[UCL] Daumerie, Aurélie[UCL] Maestre Osorio, Finoula[UCL] Aboubakar Nana, Frank[UCL] Bouzin, Caroline[UCL] Van den Eynde, Marc[UCL] (2023) Journal of visualized experiments — Vol. 196, p. e65220 [1-17] (2023)
19. • Speech

    • 

    Abstract CT192: Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer

    Ponz-Sarvisé, Mariano Élez, Elena Muñoz, Andrés Van den Eynde, Marc[UCL] Rampoldi, Antonio Gaetano Hendlisz, Alain Prenen, Hans Rodríguez, Mercedes Cano, María Teresa Chaney, Marya Escuin, Helena Pons, Vanesa Quintero, Marisol Cervantes, Andrés (2021) AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA —
20. • Journal article

    • 

    Radioembolisation(Yttrium-90 microspheres)for liver malignancies

    Van den Eynde, Marc[UCL] Lhommel, Renaud[UCL] Goffette, Pierre[UCL] Peeters, Marc Flamen, Patrick Hendlisz, Alain (2011) Belgian Journal of Medical Oncology — Vol. 5, no. 5, p. 186-192 (2011)
21. • Speech

    • 

    Significant differences in outcome between Immunoscore categories in stage I colon cancer patients

    Galon, J. Hermitte, F. Mlecnik, B. Marliot, F. Bifulco, C. Lugli, A. Nagtegaal, I. Hartmann, A. Van den Eynde, Marc[UCL] Roehrl, M. Ohashi, P. Zavadova, E. Torigoe, T. Patel, P. Wang, Y. Kawakami, Y. Marincola, F. Ascierto, P. Fox, B. Pagès, F. (2019) ESMO Congress 2019 —
22. • Speech

    • 

    Randomized, Open-Label Study of the Biological Effects of BLP25 Liposome (L-BLP25) Immunotherapy in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy: Sprint Study Design

    Ruers, T.J.M. Aust, D. Van den Eynde, Marc[UCL] Folprecht, G. Carrasco, J. Fuchs, M. Smit, J.M. Victor, A. Quaratino, S. (2012) ESMO Congress 2012 —
23. • Speech

    • 

    Exploratory analysis based on tumor location of REACHIN, a randomized, double-blinded, placebo-controlled phase 2 trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for advanced/metastatic biliary tract tumors

    Demols, A. Borbath, Ivan[UCL] Van den Eynde, Marc[UCL] Houbiers, G. Peeters, M. Marechal, R. Delaunoit, T. Goeminne, J. Laurent, S. Holbrechts, S. Paesmans, M. Van Laethem, J. (2019) ESMO Congress 2019 —
24. • Journal article

    • 

    Hypersensitivity reactions to folinic acid: mechanisms involved based on two case reports and a literature review

    Apraxine, Matveï[UCL] Van den Eynde, Marc[UCL] De Cuyper, Astrid[UCL] Pirson, Françoise[UCL] (2022) Allergy, asthma, and clinical immunology — Vol. 18, no. 1, p. 107 [1-7] (2022)
25. • Speech

    • 

    T-cell infiltration on liver colorectal metastases resected after treatment is prognostic

    Van den Eynde, Marc[UCL] Mlecnik, Bernhard Machiels, Jean-Pascal[UCL] Debetancourt, Daphné[UCL] Sempoux, Christine[UCL] Mourin, Anne[UCL] Gigot, Jean-François[UCL] Hubert, Catherine[UCL] Humblet, Yves[UCL] Haicheur, Nacilla Marliot, Florence Pages, Franck Galon, Jerome (2014) Belgian Week of Gastroenterology - XXVIth Edition — (Belgium) La Hulpe

Pages